|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, we showed miR-106a overexpression upregulated the levels of Bcl-2 and ABCG2, and downregulated the expression of P53, Bax, and RUNX3. miR-106a promotes breast cancer cell proliferation and invasion through upregulation of Bcl-2, ABCG2, and P53, and downregulation of Bax and RUNX3.
|
30570350 |
2019 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
ONCOMINE analysis was utilized to compare expression profiles of Bcl-2 family members across all major BC subgroups.
|
30374681 |
2019 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In three human breast cancer cell lines, we demonstrated that Akt-mTOR-eEF-2K pathway was involved in TBMS1-induced activation of autophagy, while Akt-mediated downregulations of Mcl-1, Bcl-xl, and Bcl-2 led to the activation of apoptosis of the breast cancer cells.
|
30315250 |
2019 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Potentiating apoptosis and modulation of p53, Bcl2, and Bax by a novel chrysin ruthenium complex for effective chemotherapeutic efficacy against breast cancer.
|
30246261 |
2019 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
BCL2 levels indicate molecular subtype and tumour proliferation status in breast cancer.
|
30069746 |
2018 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
All single- and combined-treated groups showed a significant increase in apoptosis (indicated by upregulated mRNA level of the pro-apoptotic marker Bax and downregulated mRNA level of the anti-apoptotic marker Bcl2) and a significant decrease in mRNA level of the two breast cancer related receptors EGFR and ERα, with the best effect in combined groups especially that contained the 4 compounds, as compared to vehicle-treated group.
|
30021371 |
2018 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Because BCL2 proteins are overexpressed in breast cancer and targetable by selective antagonists, we here analysed the effect of BCL2 and BCL(X)L selective inhibitors, Venetoclax and WEHI-539, on mitochondrial bioenergetics and cell death.
|
29899841 |
2018 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Some Bcl-2 family members are expressed in breast cancer and influence the response to anti-cancer therapies.
|
29876007 |
2018 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide.
|
29855616 |
2018 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, the results suggested that Bcl-2 may induce cellular metastasis in breast cancer via the epithelial-to-mesenchymal transition.
|
29844816 |
2018 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, rcdtB treatment inhibited tumor growth and induced apoptosis through inhibiting Bcl-2 expression, inflammatory responses, and activating C-erbB-2 and Cox-2 expression in breast cancer mouse model.
|
29501042 |
2018 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, the effects of BCL-2 inhibitors on drug resistant breast cancer have not yet been elucidated.
|
29496539 |
2018 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
HPV Status and Its Correlation with BCL2, p21, p53, Rb, and Survivin Expression in Breast Cancer in a Chinese Population.
|
29423411 |
2017 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Distinct from other pro-survival Bcl-2 family members, the short half-life of MCL-1 protein led us to investigate MCL-1 protein expression in a breast cancer tissue microarray and correlate this with clinical data.
|
29339815 |
2018 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Additional experiments revealed that uc.38 negatively regulated the expression of the pre-B-cell leukaemia homeobox 1 (PBX1) protein and subsequently affected the expression of Bcl-2 family members, ultimately inducing breast cancer cell apoptosis.
|
29312798 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The tumor sizes were significantly reduced in patients with HER2-positive, Tau-negative, Bcl-2-negative and high Ki67 index breast cancer.
|
29254147 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to examine the influence of intra-tumoral heterogeneity as well as inter-observer variability on the evaluation of various IHC markers with potential prognostic impact in breast cancer (BCL2, E-cadherin, EGFR, EMMPRIN and Ki-67).
|
29202620 |
2018 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The effects of LCA on breast cancer-derived MCF-7 and MDA-MB-231 cells were studied using MTT viability assays, Annexin-FITC and Akt phosphorylation assays to evaluate anti-proliferative and pro-apoptotic properties, qRT-PCR and Western blotting assays to assess the expression of the bile acid receptor TGR5 and the estrogen receptor ERα, and genes and proteins involved in apoptosis (Bax, Bcl-2, p53) and lipogenesis (SREBP-1c, FASN, ACACA).
|
28993998 |
2018 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We evaluated the efficacy of curcumin in sensitizing chemotherapy drugs through regulation of Bcl-2-mediated apoptosis in breast cancer stem-like cells (BCSCs).
|
28959140 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Since the anti-apoptotic Bcl-2 family protein myeloid cell leukemia-1 (Mcl-1) plays an important role in breast cancer cell survival and chemoresistance, we investigated if PKCη regulates Mcl-1 level.
|
28939105 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
More recently, Bcl-2 has been recognized as an important prognostic factor in breast cancer, although controversies persist with respect to the significance of its expression.
|
28801774 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Two miRNAs, hsa-miR-17-5p and hsa-miR-16-5p, were identified as having the highest associations with targeted mRNAs [such as B-cell lymphoma 2 (BCL2), small body size/mothers against decapentaplegic 3 (SMAD3) and suppressor of cytokine signaling 1 (SOCS1)] and pathways associated with epithelial-mesenchymal transitions and other processes linked with cancer metastasis (including cell cycle, adherence junctions and extracellular matrix-receptor interaction). mRNAs for two genes [HECT, UBA and WWE domain containing 1 (HUWE1) and BCL2] were found to have the highest associations with miRNAs, which were down-regulated in brain metastasis specimens of breast cancer.
|
28739740 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mechanistic studies revealed that CCL28 mediated intracellular activation of the mitogen-activated protein kinase (MAPK) signaling pathway to promote breast cancer cell proliferation and metastasis by upregulating anti-apoptotic protein Bcl-2 and suppressing cell adhesion protein β-catenin.
|
28713975 |
2017 |
|
Breast Carcinoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The regulation of BCL2 was mainly associated with methylation across the molecular subtypes of breast cancer, and luminal A and luminal B subtypes showed upregulated expression of BCL2 protein, mRNA, and hypomethylation.
|
28701032 |
2018 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, a novel folate-conjugated PEGylated cationic triblock copolymer, poly(acrylhydrazine)-block-poly(3-dimethylaminopropyl methacrylamide)-block-poly(acrylhydrazine) (PAH-b-PDMAPMA-b-PAH), was synthesized and evaluated as a stimuli-sensitive vehicle for the targeted co-delivery of doxorubicin (DOX) and Bcl-2 siRNA into breast cancer MCF-7 cells.
|
28482576 |
2017 |